ALK and non-small cell lung carcinoma: A total of 241 patients with EGFR/ALK/ROS1 (Thermo Fisher Scientific (Ion Torrent) (Waltham, MA, USA)) wild-type advanced non-small cell lung cancer (aNSCLC) and PD-L1 TPS ≥ 50% were treated with first-line P with or without PCT from June 2016 to December 2020, identified in the proof-of-concept cohort.